Table 1 Clinical and molecular characteristics of AML training and testing cohort
Variable | AML training cohort (n = 128) | AML testing cohort (n = 50) |
|---|---|---|
Age (years) | Median: 55 (range 21–69) | Median: 59 (range 24–75) |
Gender (males/females) | 68/60 | 24/26 |
Leukocytes count [109/l] | Median: 66.5 (range 1–136) | Median: 22.9 (range 0.7–218) |
Blasts in bone marrow [%] | Median: 53.4 (0–97.8) | Median: 50 (20–91.8) |
Karyotype (Grimwade 2010) | ||
Favorable | 9 (7%) | 3 (6%) |
Intermediate | 87 (68%) | 38 (76%) |
Adverse | 30 (23%) | 9 (18%) |
Not evaluable | 2 (2%) | 0 |
ELN 2017 | ||
Favorable | 33 (26%) | 19 (6%) |
Intermediate | 44 (34%) | 18 (76%) |
Adverse | 41 (32%) | 13 (18%) |
Not evaluable | 10 (8%) | 0 |
FLT3 status | ||
Wild-type | 95 (74%) | 37 (74%) |
Internal tandem duplication | 32 (25%) | 13 (26%) |
Not evaluable | 1 (1%) | 0 |
NPM1 status | ||
Wild-type | 80 (62%) | 29 (58%) |
Mutated | 43 (34%) | 21 (42%) |
Not evaluable | 5 (4%) | 0 |
Complete remission after 1st induction | 70 (55%) | 34 (68%) |